arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Contineum Therapeutics, Inc.

CTNM Health Care Biotechnology: Pharmaceutical Preparations
$8.31
▼ -0.5% Today
as of Oct 23, 16:47 ET
Last 30 days -43.93% Sep 14 → Oct 23
$6.46 $8.71 $10.95 $13.19 $15.44 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$8.24
High
$8.43
Low
$8.01
Volume
$428,769
Avg Vol
$408,475
Mkt Cap
$479M
P/E (TTM)
—
Beta
—
52w High
$17.79
52w Low
$6.72
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 12 items

Oct 13 · 14:03 MT Newswires
Baird Downgrades Contineum Therapeutics to Neutral From Outperform, Price Target is $14
Oct 12 · 15:00 Zacks
All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to Buy
Oct 12 · 12:42 InvestorsHub
Contineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial Results
▸ Show all 12 press releases & news Free account →

CTNM earnings at a glance

Contineum Therapeutics, Inc. (CTNM) is scheduled to report earnings on Thursday, October 29, 2026 — in 5 days. Analysts expect earnings per share of -$0.45, compared with -$0.45 in the same quarter last year (+0%). The options market is pricing a move of about ±39.7% after the report, a range of roughly $5.01 to $11.61 from today's $8.31. Over its last 6 reports the stock rose the next day 5 times and fell 1, moving ±3.1% on average; after the most recent report on Jul 30, 2026 it moved -1.7%. That means options currently expect more movement than CTNM has typically delivered. CTNM beat the consensus EPS estimate in 4 of its last 6 reported quarters. Implied volatility is currently 317%. The share price of $8.31 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$6.72
$18
14% of range
Avg surprise (last 6)
+7.5%
Avg reaction (last 6)
+2.5%
83% positive
Latest IV / EM
317%
EM ±39.7% · $13 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.69$-1.81$-0.93$-0.04$0.84 Actual $0.84Actual $-2.69Actual $-0.39Actual $-0.40Actual $-0.62Est $-0.56Actual $-0.62Est $-0.56Actual $-0.45Est $-0.58Actual $-0.49Est $-0.50Actual $-0.39Est $-0.55Actual $-0.40Est $-0.46 JunSepJunSepMar/2025Jun/2025Sep/20258KMar/20268K
Revenue vs Net Income Revenue Net income
$-16M$-15M$-13M$-12M$-11M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Thu Jul 30, 20268K 2026-07-30 $-0.40 $-0.46 +13.0% — -1.7% earnings
Tue May 5, 2026Mar/2026 $-0.39 $-0.55 +29.1% +37.1% +3.8% earnings
Thu Mar 5, 20268K 2026-03-05 $-0.49 $-0.50 +2.0% — +0.5% earnings
Thu Oct 30, 2025Sep/2025 $-0.45 $-0.58 +22.4% — +4.5% earnings
Tue Aug 5, 2025Jun/2025 $-0.62 $-0.56 -10.7% — +5.5% earnings
Wed May 14, 2025Mar/2025 $-0.62 $-0.56 -10.7% — +2.6% earnings
Mon Sep 30, 2024Sep 2024 $-0.40 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.39 — — — — financials
Sat Sep 30, 2023Sep 2023 $-2.69 — — — — financials
Fri Jun 30, 2023Jun 2023 $0.84 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Oct 29, 2026Sep/2026OTHER -$0.45-$0.45 0.0%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue———————$0
Cost of revenue————————
Gross profit————————
Operating income$-17M$-17M—$-15M$-18M$-18M—$-13M
Net income$-15M$-14M—$-13M$-16M$-16M—$-10M
EPS (diluted)$-0.40$-0.39——$-0.62$-0.62—$-0.40

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$15M$20M$76M$43M$21M$22M$22M$41M
Inventory————————
Total current assets$243M$253M$268M$185M$177M$192M$206M$215M
Total assets$250M$261M$277M$191M$183M$198M$213M$216M
Long-term debt————————
Total liabilities$11M$11M$16M$10M$11M$13M$15M$6M
Total equity$240M$250M$261M$180M$171M$185M$198M$210M

Implied volatility — last 90 days

91%283%476%668%860% Jun 08 — IV 322% · EM ±42.5%Jun 09 — IV 349% · EM ±43.7%Jun 10 — IV 382% · EM ±45.1%Jun 11 — IV 389% · EM ±43.0%Jun 12 — IV 420% · EM ±42.9%Jun 15 — IV 593% · EM ±42.9%Jun 19 — IV 195% · EM ±43.1%Jun 23 — IV 212% · EM ±43.5%Jun 24 — IV 195% · EM ±39.0%Jun 25 — IV 191% · EM ±37.4%Jun 26 — IV 127% · EM ±24.3%Jun 29 — IV 150% · EM ±26.7%Jun 30 — IV 213% · EM ±36.6%Jul 01 — IV 209% · EM ±34.9%Jul 02 — IV 205% · EM ±33.1%Jul 03 — IV 212% · EM ±33.1%Jul 06 — IV 196% · EM ±27.2%Jul 07 — IV 265% · EM ±35.0%Jul 08 — IV 273% · EM ±34.2%Jul 09 — IV 277% · EM ±32.7%Jul 10 — IV 229% · EM ±25.3%Jul 13 — IV 418% · EM ±34.9%Jul 14 — IV 484% · EM ±35.0%Jul 15 — IV 457% · EM ±27.0%Jul 20 — IV 174% · EM ±41.2%Jul 21 — IV 201% · EM ±46.8%Jul 22 — IV 160% · EM ±36.7%Jul 23 — IV 167% · EM ±37.6%Jul 24 — IV 161% · EM ±35.6%Jul 27 — IV 173% · EM ±36.1%Jul 28 — IV 173% · EM ±35.3%Jul 30 — IV 119% · EM ±23.3%Aug 03 — IV 209% · EM ±37.0%Aug 04 — IV 223% · EM ±38.4%Aug 05 — IV 218% · EM ±36.3%Aug 06 — IV 220% · EM ±35.5%Aug 07 — IV 219% · EM ±34.2%Aug 11 — IV 255% · EM ±33.7%Aug 12 — IV 256% · EM ±32.0%Aug 17 — IV 379% · EM ±31.7%Aug 18 — IV 427% · EM ±30.9%Aug 24 — IV 150% · EM ±31.3%Aug 25 — IV 143% · EM ±29.3%Aug 26 — IV 147% · EM ±29.4%Aug 27 — IV 108% · EM ±21.2%Aug 28 — IV 156% · EM ±29.9%Aug 31 — IV 188% · EM ±33.3%Sep 01 — IV 118% · EM ±20.2%Sep 02 — IV 196% · EM ±32.8%Sep 08 — IV 143% · EM ±18.8%Sep 09 — IV 216% · EM ±27.1%Sep 14 — IV 479% · EM ±40.0%Sep 15 — IV 530% · EM ±38.4%Sep 16 — IV 603% · EM ±35.6%Sep 17 — IV 861% · EM ±36.0%Sep 21 — IV 177% · EM ±36.9%Sep 22 — IV 124% · EM ±25.4%Sep 23 — IV 220% · EM ±44.0%Sep 25 — IV 92% · EM ±17.5%Sep 28 — IV 166% · EM ±29.5%Sep 29 — IV 234% · EM ±40.2%Sep 30 — IV 225% · EM ±37.5%Oct 01 — IV 259% · EM ±42.0%Oct 02 — IV 239% · EM ±37.3%Oct 05 — IV 267% · EM ±37.0%Oct 07 — IV 317% · EM ±39.7%

Sector peers

EVMN
Evommune, Inc.
$472M $5.10-1.4%
ARVN
Arvinas, Inc.
$487M $7.30-3.4%
ACRS
Aclaris Therapeutics, Inc.
$500M $3.75-1.6%
CBIO
Crescent Biopharma, Inc.
$501M $12.82-2.7%
PBYI
Puma Biotechnology Inc
$506M $11.02+1.1%
DMAC
DiaMedica Therapeutics Inc.
$450M $8.72+0.3%

CTNM earnings FAQ

When is CTNM's next earnings date?

Contineum Therapeutics, Inc. is expected to report on October 29, 2026.

What is CTNM's expected move for earnings?

Options currently price a move of about ±39.7%, or $3.30 per share either way from $8.31.

How does CTNM stock usually react to earnings?

Across the last 6 reports the average next-day move was ±3.1%, up 5 times and down 1 times.

What EPS are analysts expecting from Contineum Therapeutics, Inc.?

The consensus estimate is -$0.45 per share, versus -$0.45 a year ago.

What is CTNM's implied volatility?

CTNM's at-the-money implied volatility is about 317% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in